Search research articles
Contact Us
Filters
Showing results (1-10 of 17) with videos related to
Page
of 2
Sort By:
Nursing Philosophy : an International Journal for Healthcare Professionals
|
September 16, 2010
Destabilizing the 'equipoise' framework in clinical trials: prioritizing non-exploitation as an ethical framework in clinical research
Douglas E Schlichting
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists
|
June 6, 2009
Protein C in critical illness
Henry J Mann, Mary A Short, Douglas E Schlichting
Trials
|
October 10, 2021
Clinical effectiveness and safety of baricitinib for the treatment of juvenile idiopathic arthritis-associated uveitis or chronic anterior antinuclear antibody-positive uveitis: study protocol for an open-label, adalimumab active-controlled phase 3 clinical trial (JUVE-BRIGHT)
Athimalaipet V Ramanan, Catherine M Guly, Stuart Y Keller, et al.
The Journal of Rheumatology
|
August 17, 2017
Safety and Efficacy of Baricitinib Through 128 Weeks in an Open-label, Longterm Extension Study in Patients with Rheumatoid Arthritis
Edward C Keystone, Mark C Genovese, Douglas E Schlichting, et al.
Clinical and Experimental Rheumatology
|
February 16, 2019
The effect of JAK1/JAK2 inhibition in rheumatoid arthritis: efficacy and safety of baricitinib
Ernest H S Choy, Corinne Miceli-Richard, Miguel A González-Gay, et al.
Microvascular Research
|
December 7, 2010
Circulating endothelial and endothelial progenitor cells in patients with severe sepsis
Douglas E Schlichting, Aaron B Waxman, Lee A O'Brien, et al.
ACR Open Rheumatology
|
December 16, 2021
Pain Reduction in Rheumatoid Arthritis Patients Who Use Opioids: A Post Hoc Analysis of Phase 3 Trials of Baricitinib
Janet E Pope, Yvonne C Lee, Jeffrey R Curtis, et al.
Arthritis & Rheumatology (Hoboken, N.J.)
|
December 29, 2016
Effects of Baricitinib on Lipid, Apolipoprotein, and Lipoprotein Particle Profiles in a Phase IIb Study of Patients With Active Rheumatoid Arthritis
Joel M Kremer, Mark C Genovese, Edward Keystone, et al.
Annals of the Rheumatic Diseases
|
November 2, 2016
Patient-reported outcomes from a randomised phase III study of baricitinib in patients with rheumatoid arthritis and an inadequate response to biological agents (RA-BEACON)
Josef S Smolen, Joel M Kremer, Carol L Gaich, et al.
Rheumatology (Oxford, England)
|
February 8, 2018
Response to baricitinib based on prior biologic use in patients with refractory rheumatoid arthritis
Mark C Genovese, Joel M Kremer, Cynthia E Kartman, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 17) with videos related to
Sort By:
Page
of 2
Nursing Philosophy : an International Journal for Healthcare Professionals
|
September 16, 2010
Destabilizing the 'equipoise' framework in clinical trials: prioritizing non-exploitation as an ethical framework in clinical research
Douglas E Schlichting
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists
|
June 6, 2009
Protein C in critical illness
Henry J Mann, Mary A Short, Douglas E Schlichting
Trials
|
October 10, 2021
Clinical effectiveness and safety of baricitinib for the treatment of juvenile idiopathic arthritis-associated uveitis or chronic anterior antinuclear antibody-positive uveitis: study protocol for an open-label, adalimumab active-controlled phase 3 clinical trial (JUVE-BRIGHT)
Athimalaipet V Ramanan, Catherine M Guly, Stuart Y Keller, et al.
The Journal of Rheumatology
|
August 17, 2017
Safety and Efficacy of Baricitinib Through 128 Weeks in an Open-label, Longterm Extension Study in Patients with Rheumatoid Arthritis
Edward C Keystone, Mark C Genovese, Douglas E Schlichting, et al.
Clinical and Experimental Rheumatology
|
February 16, 2019
The effect of JAK1/JAK2 inhibition in rheumatoid arthritis: efficacy and safety of baricitinib
Ernest H S Choy, Corinne Miceli-Richard, Miguel A González-Gay, et al.
Microvascular Research
|
December 7, 2010
Circulating endothelial and endothelial progenitor cells in patients with severe sepsis
Douglas E Schlichting, Aaron B Waxman, Lee A O'Brien, et al.
ACR Open Rheumatology
|
December 16, 2021
Pain Reduction in Rheumatoid Arthritis Patients Who Use Opioids: A Post Hoc Analysis of Phase 3 Trials of Baricitinib
Janet E Pope, Yvonne C Lee, Jeffrey R Curtis, et al.
Arthritis & Rheumatology (Hoboken, N.J.)
|
December 29, 2016
Effects of Baricitinib on Lipid, Apolipoprotein, and Lipoprotein Particle Profiles in a Phase IIb Study of Patients With Active Rheumatoid Arthritis
Joel M Kremer, Mark C Genovese, Edward Keystone, et al.
Annals of the Rheumatic Diseases
|
November 2, 2016
Patient-reported outcomes from a randomised phase III study of baricitinib in patients with rheumatoid arthritis and an inadequate response to biological agents (RA-BEACON)
Josef S Smolen, Joel M Kremer, Carol L Gaich, et al.
Rheumatology (Oxford, England)
|
February 8, 2018
Response to baricitinib based on prior biologic use in patients with refractory rheumatoid arthritis
Mark C Genovese, Joel M Kremer, Cynthia E Kartman, et al.
Page
of 2